Atigotatug

DB14831InvestigationalProtein Based Therapies

BMS-986012 is a human antifucosyl-GM1 antibody. It is under investigation in clinical trial NCT02815592 (Trial of BMS-986012 in Combination With Platinum and Etoposide).

Mechanism: Pharmacologically active on Low affinity immunoglobulin gamma Fc region receptor III-A
Curator reviewed
Also known as: BMS-986012 (HUMAN ANTIFUCOSYL-GM1 ANTIBODY) · immunoglobulin G1-kappa, anti-[Fucosyl-GM1 (fucosylated monosialoganglioside 1)], Homo sapiens monoclonal antibody; H-gamma1 heavy chain Homo sapiens (1-452) [VH (Homo sapiens IGHV3-48*02 (90.7%) -(IGHD) -IGHJ3*01 (92.3%) M123>T (117), CDR-IMGT [8.8.15]
Code names: BMS-986012

Resolves to

Compound

UNIIQ8PK97HY9BCAS1894272-37-7

Targets

P08637FCGR3A

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Atigotatug, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account